Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0OGZEE)
| ADC Name |
Mirzotamab clezutoclax
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
mirzotamab clezutoclax; ABBV-155
Click to Show/Hide
|
|||||
| Organization |
AbbVie (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Mirzotamab
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
clezutoclax
|
Payload Info | ||||
| Payload Target |
Bcl-2-like protein 1 (BCL2L1)
|
Target Info | ||||
| Linker Name |
Val-Ala dipeptide linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
clezutoclax
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Lung cancer | ||||
| Breast cancer |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion: Solid tumor patients (Part 2a: SCLC; Part 2b: NSCLC/HR+HER2- breast cancer) with measurable disease, ECOG ≤2, prior therapy failure. Breast cancer patients must have CDK4/6 inhibitor failure; NSCLC patients require targeted therapy if actionable mutations present. Exclusion: Active CNS metastases, Grade≥2 neuropathy, unresolved toxicities, active hepatitis/HIV, significant cardiac history, or hypersensitivity to study drug components. Taxane-exposed patients require 2-month washout.
Click to Show/Hide
|
||||
| Administration Dosage |
Participants will be administered ABBV-155 (various doses).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03595059 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include MTD/RPTD determination during dose escalation (21-day evaluation) and ORR assessment (RECIST 1.1) with 2-6 month follow-up in expansion phases.
|
||||
| Other Endpoint |
Secondary objectives comprise AE monitoring (12 months), efficacy measures (DOR/CR/PFS/OS), PK parameters (Cmax/Tmax/AUCt/AUCinf/t1/2 over 48 days), and cardiac safety (QTcF changes).
|
||||
References